China Economic Net, Beijing, March 7 (Reporter Guo Wenpei) Although the development of China's pharmaceutical industry has entered a new stage, Li Yan, a representative of the National People's Congress and president of Qilu Pharmaceutical, has never stopped thinking and practicing on the issue of high-quality development of the pharmaceutical industry over the years. To this end, at this year's two sessions, representative Li Yan brought suggestions on supporting the innovation, upgrading and development of the national pharmaceutical industry.
Li Yan, deputy to the National People's Congress and president of Qilu Pharmaceutical (photo provided by the interviewee).
At present, the development of China's pharmaceutical industry has entered a new stage, the reform of the medical and health system has been further promoted, and the number of approved new drugs has reached new highs. However, the development of China's pharmaceutical industry is a systematic project, and there are still problems such as 'involution' in the industry, few high-quality innovation achievements, and weak overall international competitiveness. In Li Yan's view, on the existing basis, through the systematic construction and systematic reshaping of policies, and further give full play to the concentrated combination effect of policies, the new vitality of the national pharmaceutical industry and enterprise development will be fully released.
As for how to put it into practice, Deputy Li Yan pointed out that breakthroughs can be sought in four aspects.
First, it is recommended to adhere to the system concept and continuously optimize the drug research and development environment. Deputy Li Yan believes that in the new era, China's drug supervision is facing new tasks, and it is often difficult to "want, want, and demand", and it is also necessary to bear the challenges of supervision, development, and interests in multiple periods. Therefore, it is suggested that when carrying out the top-level design of the national drug regulatory system, it is necessary not only to ensure the scientificity of supervision, but also to coordinate the interests of the people and the development of the industry; It not only encourages innovation, but also faces up to the development stage and reality of China's pharmaceutical industry, and gives guidance and support to the problems encountered in enterprise innovation while avoiding the "involution" caused by low-level innovation and avoiding the "protection" of low-level innovative products. At the same time, it is recommended that relevant departments strengthen policy consultation and inter-ministerial linkage, jointly plan comprehensive policies, connect specialized policies, closely cooperate to promote the reform of the medical and health system, and strengthen the coordinated development and comprehensive management of medical insurance, medical treatment and medicine.
Second, it is recommended to support enterprises to enhance their core competitiveness and effectively lay the foundation for the development of the national pharmaceutical industry. Representative Li Yan believes that the leading pharmaceutical enterprises are currently in the climbing period of "imitation to innovation", and they need to increase the release of policy dividends and continuously cultivate and consolidate the main position of enterprise innovation. It is recommended to explore the establishment of direct reporting channels for the achievements and scientific research projects of key science and technology enterprises, so as to give more "sunshine and rain" to enterprises with real innovation strength and ability.
Thirdly, it is suggested to build a collaborative innovation transformation mechanism to improve the efficiency of the transformation of scientific research achievements. Deputy Li Yan believes that in a good innovation ecosystem, collaborative innovation in production, learning, research, medicine and other links is very important. It is recommended to give full play to the advantages of the new first-class system and carry out organized scientific and technological innovation. At the same time, leading enterprises are encouraged to join forces with universities and scientific research institutes, concentrate the most advantageous resources, and organize the top, most senior and strongest units in the field in China to form the strongest "team" to jointly build a national industrial innovation center and jointly undertake major national science and technology projects. At the same time, it has built a "bridge" for the transformation of achievements between enterprises, universities and scientific research institutes, and built a collaborative innovation and transformation mechanism of "setting up a platform, entrepreneurs asking questions, and scientists answering questions".
Fourth, it is recommended to further improve market access and other policies to ensure sustainable development. Representative Li Yan believes that it is necessary to fully consider the actual characteristics of innovative drugs, and comprehensively consider and integrate solutions in the top-level design and specific implementation of market access. For example, in view of the current price limit requirements for innovative drugs in various places.
1. For policy differences such as inconsistent paths and inconsistent definition standards for innovative drugs, it is recommended that the medical insurance department standardize and clarify the scope and rules of newly listed innovative drugs, and open a fast network channel to ensure that innovative drugs can obtain network access qualifications in a timely manner after they are listed.
*: China Economic Net.